The cancer drugs fund (CDF) transitioned to a new model last July (see our CDF page on MAP for more detail). All treatments previously funded through the CDF have since been undergoing a reviewed by NICE.
NICE is now halfway through its review process and so far all cancer drugs have been recommended for routine use in the NHS. Companies have provided discounts and in some cases additional evidence meaning the drugs can be considered cost effective for routine NHS use. Patients will have routine access to more cancer drugs as companies have dropped their prices as part of the reformed CDF process.